R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.

Cancer Med · 2021 · PMC7926012 · PMID 33492774

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The EFS probability showed a trend to being higher in the R‐COMP arm, but PFS and OS were similar in both arms, and in line with other studies. 19 , 20 , 23 There are some limitations in this study that should be mentioned.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.